Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

Journal of Clinical Oncology

Volumn 16, Issue 10, 1998, Pages 3345-3352

  Bookman, Michael A ^a   Malmström, Henric ^a   Bolis, Giorgio ^a   Gordon, Alan ^a   Lissoni, Andrea ^a   Krebs, Jacqueline B ^a   Fields, Scott Z ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; PACLITAXEL; PLATINUM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG ACTIVITY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; HUMAN; INFUSION; MAJOR CLINICAL STUDY; NEUTROPENIA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0031786482     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.10.3345     Document Type: Article

References (34)

1. Young RC, Perez CA, Hoskins WJ: Cancer of the ovary, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer Principles and Practice of Oncology (ed 4). Philadelphia, PA, Lippincott, 1993, pp 1126-1263
2. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New Engl J Med 334:1-6, 1996
3. Cannistra SA: Cancer of the ovary. N Engl J Med 329:1550-1559, 1993
4. Ozols, RF: Treatment of ovarian cancer: Current status. Semin Oncol 21:1-9, 1994 (suppl 6)
5. Neijt JP, ten Bokkel Huinink W, van Der Berg M, et al: Long-term survival in ovarian cancer. Eur J Cancer 27:1367-1372, 1991
6. Thigpen JT, Blessing JA, Vance RB, et al: Chemotherapy in ovarian carcinoma: Present role and future prospects. Semin Oncol 16:58-65, 1989
7. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994
8. Hsiang YH, Liu LF: Identification of mammalian DNA topoisomerase I as intracellular targets of the anticancer drug camptothecin. Cancer Res 48:1722-1726, 1988
9. Creemers GJ, Lund B, Verveiwj J: Topoisomerase I inhibitors: Topotecan and irinotecan. Cancer Treat Rev 20:73-96, 1994
10. Patresi G, Tortoreto M, Giaridini R, et al: Successful local regional therapy with topotecan and of intraperitoneally grown human ovarian carcinoma xenografts. Br J Cancer 71:525-528, 1995
11. Burris HA III, Hanauske AR, Johnson RK, et al: Activity of topotecan, a new topoisomerase I inhibitor against human tumor colony-forming units in vitro. J Natl Cancer Inst 84:1816-1820, 1992
12. Houghton PJ, Cheshire PJ, Myers L, et al: Evaluation of 9-dimethylaminomethyl-10-hydroxycampothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 31:229-239, 1992
13. Rowinsky EK, Grochow LB, Hendricks CB, et al: Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J Clin Oncol 10:647-656, 1992
14. Saltz L, Sirott M, Young C, et al: Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 85:1499-1507, 1993
15. Verweij J, Lund B, Beijen J, et al: Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 4:673-678, 1993
16. Kudelka AP, Tresukosol D, Edwards C, et al: Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 14:1552-1557, 1996
17. Armstrong D, Rowinsky E, Donehower R, et al: A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer. Proc Am Soc Clin Oncol 14:A769, 1995 (abstr)
18. Creemers GJ, Bolis G, Gore M, et al: Topotecan, an active drug in a second-line treatment of epithelial ovarian cancer: Results of a large European phase II study. J Clin Oncol 14:3056-3061, 1996
19. Hochster H, Speyer J, Runowicz C, et al: Phase II study of topotecan (TPT) 21-day infusion in platinum-treated ovarian cancer: A highly active regimen (A NYGOG study). Proc Am Soc Clin Oncol 15:A775, 1996 (abstr)
20. Ten Bokkel Huinink W, Gore M, Carmichael J, et al: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183-2193, 1997
21. National Cancer Institute: Guidelines for Reporting Adverse Reactions. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute, 1988
22. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No 48. Geneva, Switzerland, World Health Organization, 1979
23. Schink JC, Harris LS, Grosen EA, et al: Altretamine (Hexalen): An effective salvage chemotherapy after paclitaxel (Taxol) in women with recurrent platinum-resistant ovarian cancer. Proc Am Soc Clin Oncol 14:A770, 1995 (abstr)
24. Muggia F, Hainsworth J, Jeffers S, et al: Phase II study of liposal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15:987-993, 1997
25. Shapiro JD, Millaward MJ, Rischin D, et al: Activity of gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel. Gynecol Oncol 63:89-93, 1996
26. Markman M: Ifosfamide in the treatment of ovarian cancer. Semin Oncol 23:47-49, 1996 (suppl 6)
27. Kavanagh JJ, Tresukosol D, Edwards CL, et al: Carboplatin reinduction after taxane in patients with platinum refractory-epithelial ovarian cancer. J Clin Oncol 13:1584-1588, 1995
28. Tresukosol D, Kuldeka AP, Gonzales de Leon C, et al: Paclitaxel retreatment in patients with platinum and paclitaxel resistant ovarian cancer. Eur J Gynecol Oncol 17:188-191, 1996
29. Gwyther S, Bolis G, Gore ME, et al: Experience with independent radiological review during a topotecan trial in ovarian cancer. Ann Oncol 8:463-468, 1997
30. Katz EJ, Vicks JS, Kling KM, et al: Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells. Eur J Cancer 26:724-727, 1990
31. Drewinko B, Green C, Loo TL, et al: Combination chemotherapy in vitro with cis-dichlorodiammine platinum. Cancer Treat Rep 60:1619-1625, 1976
32. Kaufmann SH, Peereboom D, Buckwalter CA, et al: Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 88:734-741, 1996
33. Rowinsky E, Grochow L, Ettinger D, et al: Sequence-dependent effects of topotecan (T) and cisplatin (C) in a phase I and pharmacokinetic (PK) study. Proc Am Soc Clin Oncol 13:142, 1994 (abstr)
34. Saltz L, Kanowitz J, Schwartz G, et al: Phase I trial of cisplatin (DDP) plus topotecan (T) on a daily X 5 schedule in patients with advanced solid tumors. Proc Am Soc Clin Oncol 14:475, 1995 (abstr)